AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CSBR

CHAMPIONS ONCOLOGY, INC.

Price · $CSBRvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CSBR in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CSBR in the last 30 days.

Top stories · $CSBRMore →
MAY 2·MarketBeatMed

Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving Average - What's Next?

Champions Oncology (NASDAQ:CSBR) recently traded below its 200-day moving average, reaching $5.90, significantly lower than its $6.46 average. Analyst sentiment is bearish, with a "Sell" consensus rating from MarketBeat and a downgrade from Weiss Ratings. Institutional ownership is notable at 41.3%, though mixed, as several funds recently adjusted their positions in the company, which has an $86 million market cap and a negative P/E ratio.

MAR 17·Investing.com Nigeria

Champions Oncology reports Q3 revenue of $16.6 million

Champions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, largely due to the absence of a $4.5 million data license transaction present in the prior year. The company posted a net loss of $279,000 for the quarter and adjusted EBITDA of $574,000. Despite trading near its 52-week low, InvestingPro analysis suggests the stock is currently overvalued.

MAR 12·Investing.com

Champions Oncology reports Q3 revenue of $16.6 million

Champions Oncology (NASDAQ: CSBR) reported a Q3 fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, primarily due to the absence of a large data license transaction from the prior year. Despite a 32% increase in study service revenue, the company posted a net loss of $279,000 and adjusted EBITDA of $574,000, significantly lower than the previous year. Costs also rose, but the company finished the quarter with $7.1 million in cash and no debt.

News on $CSBR